Vincenza Nigro

Corporate Officer/Principal at HANSA BIOPHARMA AB

Health Technology

Consumer Services

Finance

Profile

Vincenza Nigro is currently the Vice President-Global Medical Affairs at Hansa Biopharma AB since 2018.
Prior to this, she was the Head-Medical Affairs at Veloxis Pharmaceuticals A.
Nigro holds an MBA from the Massachusetts Institute of Technology and an undergraduate degree from Fairleigh Dickinson University.

Latest news about Vincenza Nigro

Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients	22-07-11	AQ
Transcript : Hansa Biopharma AB - Analyst/Investor Day	20-10-29
Transcript : Hansa Medical AB, Q3 2018 Earnings Call, Nov 01, 2018	18-11-01
Hansa Medical Announces Appointment of Vincenza Nigro as Vice President, Global Medical Affairs	18-09-17	CI
Veloxis Pharmaceuticals A/S Announces Executive Appointments	14-06-03	CI

Vincenza Nigro active positions

Companies	Position	Start
HANSA BIOPHARMA AB	Corporate Officer/Principal	2018-09-16

All active positions of Vincenza Nigro

Former positions of Vincenza Nigro

Companies	Position	End
VELOXIS PHARMACEUTICALS A/S	Chief Tech/Sci/R&D Officer	-

See the detail of Vincenza Nigro's experience

Training of Vincenza Nigro

Fairleigh Dickinson University	Undergraduate Degree
Massachusetts Institute of Technology	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Vincenza Nigro's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
HANSA BIOPHARMA AB	Health Technology

Private companies	1
Veloxis Pharmaceuticals A/S Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.	Health Technology